A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants

Summary

The goal of this intervention study is to evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HXN5003 in Healthy Participants.The main parameters it aims to answer are: 1. Does a single dose of HXN5003 in healthy participants impact the safety, tolerability and pharmacokinetic profiles? 2. Will immunogenicity of HXN5003 in healthy participants be altered? This study will be compared against a Placebo which contains the same inactive ingredients as those of HXN5003, but without the active ingredient.

Timeline

Start

2026-05-27

Primary completion

2027-03-18

Completion

2027-04-16

Drugs

Indications